SARS MERS Spike Antibody
Middle East respiratory syndrome coronavirus, Human betacoronavirus 2c EMC/2012, MERS-CoV, MERS, MERSCoV SP, Spike glycoprotein, S glycoprotein, S, Spike protein, E2, Peplomer protein.
Sterile filtered colorless solution.
Description
Product Specs
The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has been a concern since April 2012, with cases identified globally. Belonging to the coronavirus family, which also includes the common cold and SARS (severe acute respiratory syndrome), coronaviruses are known for causing severe illnesses with high mortality rates. MERS-CoV, a novel type of SARS within this family, leads to severe pneumonia characterized by sudden and serious respiratory illness, also associated with high mortality rates. As of January 27th, 2015, the World Health Organization (WHO) has reported 956 human cases, including 351 deaths, with expectations of further cases. A key structural protein in MERS-CoV, similar to other coronaviruses, is the large surface spike glycoprotein. This protein, situated on the virion surface, facilitates binding and entry into the target cell. The spike protein consists of two domains, S1 and S2. The S1 domain plays a crucial role in cellular tropism and interaction with the target cell, while the S2 domain is responsible for membrane fusion. The C-terminal region of the S1 domain houses a receptor binding domain, making it a potential target for vaccine development and serving as an antigen for diagnosis.
A clear, colorless solution that has been sterilized by filtration.
The solution has a concentration of 1mg/ml and contains the following components: Phosphate-Buffered Saline (pH 7.4), 0.02% Sodium Azide, and 10% Glycerol.
For short-term storage (up to 1 month), keep at 4°C. For extended storage, store at -20°C. It's important to avoid repeated freezing and thawing cycles.
The product is stable for 12 months when stored at -20°C and for 1 month at 4°C.
The SARS MERS Spike antibody has undergone ELISA analysis to verify its specificity and reactivity. However, optimal results require titration for each specific application due to varying experimental conditions.
Middle East respiratory syndrome coronavirus, Human betacoronavirus 2c EMC/2012, MERS-CoV, MERS, MERSCoV SP, Spike glycoprotein, S glycoprotein, S, Spike protein, E2, Peplomer protein.
SARS MERS Spike antibody was purified from mouse ascitic fluids by protein-A affinity chromatography.
PAT40G7AT
Recombinant MERS-CoV Spike (18-1296aa) purified from Baculovirus.
IgG1 kappa.
Product Science Overview
The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a highly pathogenic virus that emerged in 2012 in Saudi Arabia. It belongs to the betacoronavirus genus and is known for causing severe respiratory illness in humans. The virus is characterized by its spike (S) protein, which plays a crucial role in the virus’s ability to infect host cells. The spike protein is a primary target for neutralizing antibodies and vaccine development.
The spike protein of MERS-CoV is a class I fusion protein that facilitates the virus’s entry into host cells. It consists of two subunits: S1 and S2. The S1 subunit contains the receptor-binding domain (RBD), which binds to the host cell receptor dipeptidyl peptidase 4 (DPP4 or CD26). The S2 subunit mediates the fusion of the viral and host cell membranes, allowing the viral genome to enter the host cell .
Mouse anti MERS-CoV spike antibodies are monoclonal antibodies produced by immunizing mice with the MERS-CoV spike protein or its fragments. These antibodies are highly specific to the spike protein and are used in various research and diagnostic applications.
Production
The production of mouse anti MERS-CoV spike antibodies involves several steps:
- Immunization: Mice are immunized with the MERS-CoV spike protein or its fragments. The immunogen can be produced using recombinant DNA technology in cell lines such as Chinese Hamster Ovary (CHO) cells.
- Hybridoma Formation: B cells from the immunized mice are fused with myeloma cells to create hybridoma cells. These hybridomas can produce large quantities of monoclonal antibodies.
- Screening and Selection: Hybridomas are screened for the production of antibodies that specifically bind to the MERS-CoV spike protein. Positive clones are selected and expanded.
- Purification: The monoclonal antibodies are purified from the hybridoma culture supernatant using protein A or G affinity chromatography .
Applications
Mouse anti MERS-CoV spike antibodies are used in various applications, including:
- Enzyme-Linked Immunosorbent Assay (ELISA): These antibodies are used to detect the presence of MERS-CoV spike protein in samples.
- Western Blotting: They are used to identify and quantify the spike protein in cell lysates or purified preparations.
- Flow Cytometry: These antibodies can be used to analyze the expression of the spike protein on the surface of infected cells.
- Neutralization Assays: They are used to assess the ability of the antibodies to neutralize the virus by blocking the interaction between the spike protein and the host cell receptor .
